)
)
)
Cytosolix, Inc.
The Cytosolix platform takes known tox-limited small molecule oncology drugs and enhances their therapeutic indices by replacing variable groups with our proprietary weakly-acidic Tumor Activated Permeability (TAP) moieties to target tumor acidity. With this TAP platform, Cytosolix has developed preclinical-ready, oral, DNA-damage repair and cell-cycle lead drugs (1st-in-class targets) that virtually eliminate (84-93%) the dose-limiting myelosuppression in animal models. We are seeking ~$35M in Series A financing and BD partnerships to progress our lead candidates through IND/FIH and to expand our platform. The proprietary datasets and processes we have developed uniquely enable us to generate novel drug derivatives with enhanced therapeutic indices and fresh composition of matter IP across the small molecule oncology landscape.
Address
New HavenConnecticut
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)